» Articles » PMID: 38001672

DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish Xenografts

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001672
Authors
Affiliations
Soon will be listed here.
Abstract

Circulating tumor cells (CTCs) serve as crucial metastatic precursor cells, but their study in animal models has been hindered by their low numbers. To address this challenge, we present DanioCTC, an innovative xenograft workflow that overcomes the scarcity of patient-derived CTCs in animal models. By combining diagnostic leukapheresis (DLA), the Parsortix microfluidic system, flow cytometry, and the CellCelector setup, DanioCTC effectively enriches and isolates CTCs from metastatic breast cancer (MBC) patients for injection into zebrafish embryos. Validation experiments confirmed that MDA-MB-231 cells, transplanted following the standard protocol, localized frequently in the head and blood-forming regions of the zebrafish host. Notably, when MDA-MB-231 cells spiked (i.e., supplemented) into DLA aliquots were processed using DanioCTC, the cell dissemination patterns remained consistent. Successful xenografting of CTCs from a MBC patient revealed their primary localization in the head and trunk regions of zebrafish embryos. DanioCTC represents a major step forward in the endeavors to study the dissemination of individual and rare patient-derived CTCs, thereby enhancing our understanding of metastatic breast cancer biology and facilitating the development of targeted interventions in MBC. Summary statement: DanioCTC is a novel workflow to inject patient-derived CTCs into zebrafish, enabling studies of the capacity of these rare tumor cells to induce metastases.

Citing Articles

[Modification with IL-21 and CCL19 enhances killing efficiency and tumor infiltration of NKP30 CAR-T cells in lung cancer].

Zhou Z, Liu S, Li J, Chen M, Lin H, Chen Y Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(10):1926-1936.

PMID: 39523093 PMC: 11526451. DOI: 10.12122/j.issn.1673-4254.2024.10.11.

References
1.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

2.
Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A . Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products. Clin Chem. 2019; 65(4):549-558. DOI: 10.1373/clinchem.2018.296814. View

3.
Rossi E, Rugge M, Facchinetti A, Pizzi M, Nardo G, Barbieri V . Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. Oncoscience. 2015; 1(1):49-56. PMC: 4295764. DOI: 10.18632/oncoscience.8. View

4.
Spoorendonk K, Peterson-Maduro J, Renn J, Trowe T, Kranenbarg S, Winkler C . Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. Development. 2008; 135(22):3765-74. DOI: 10.1242/dev.024034. View

5.
Kadamkulam Syriac A, Nandu N, Leone J . Central Nervous System Metastases from Triple-Negative Breast Cancer: Current Treatments and Future Prospective. Breast Cancer (Dove Med Press). 2022; 14:1-13. PMC: 8760391. DOI: 10.2147/BCTT.S274514. View